Company intelligence / Profile preview

RenoVate Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

RenoVate Therapeutics develops regenerative biomolecules designed to repair and rejuvenate the kidneys. The company focuses on innovative treatments for chronic kidney disease and originated as a spin-off from Sheba Medical Center[1][2][3]. There are no public reports of clinical trial results or advanced-stage programs.

Therapeutic areas: Nephrology
Modalities: Regenerative biomolecules
Industry: Biotech

Drug pipeline

1 asset

KOSEC01

Preclinical

Partnerships

Sheba Medical Center (spin-off relationship)[1]

Beyond the preview

Go deeper on RenoVate Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RenoVate Therapeutics.

Explore the full profile